In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Vical nets $31.7mm through FOPO

Executive Summary

Vical Inc. (DNA delivery technologies) has netted $31.7mm through the follow-on public offering of 15mm common shares at $2.25 each. The financing comes at a time when partner Sanofi announced the failure of Phase III Temusi to produce blood vessel growth in critical limb ischemia patients and another ally, AnGes, pulled the Japanese regulatory filing for Collategene, also for critical limb ischemia.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies